Ranolazine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Hypertrophic Cardiomyopathy

Conditions

Hypertrophic Cardiomyopathy

Trial Timeline

Nov 1, 2012 → May 1, 2016

NCT ID

NCT01721967

About Ranolazine

Ranolazine is a approved stage product being developed by Gilead Sciences for Hypertrophic Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01721967. Target conditions include Hypertrophic Cardiomyopathy.

What happened to similar drugs?

2 of 12 similar drugs in Hypertrophic Cardiomyopathy were approved

Approved (2) Terminated (0) Active (10)

✅MavacamtenBristol Myers SquibbApproved

🔄Mavacamten + PlaceboLianBioPhase 3

🔄Mavacamten + PlaceboBristol Myers SquibbPhase 3

🔄MavacamtenBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02360397	Phase 2	Completed	Dec 1, 2014	Feb 23, 2018	Ventricular Premature Complexes
NCT02251457	Phase 1	Completed	Aug 1, 2014	Dec 18, 2017	Myotonia Congenita
NCT01721967	Approved	Completed	Nov 1, 2012	May 1, 2016	Hypertrophic Cardiomyopathy
NCT01705509	Pre-clinical	Terminated	Sep 1, 2012	Mar 31, 2017	Cardiomyopathy
NCT01804543	Pre-clinical	UNKNOWN	Jun 1, 2012	Dec 1, 2014	Angina
NCT01435174	Approved	Completed	Oct 1, 2011	Mar 1, 2013	End-stage Renal Disease
NCT02133352	Approved	Completed	Jul 1, 2011	May 1, 2014	Pulmonary Hypertension
NCT01334203	Approved	Withdrawn	May 1, 2011	Dec 1, 2012	Angina Pectoris
NCT01304095	Approved	UNKNOWN	Jan 1, 2011	Nov 1, 2013	Coronary Artery Disease
NCT01174173	Phase 3	Completed	Jun 1, 2010	Oct 1, 2014	Angina
NCT01163734	Phase 2	Completed	Apr 1, 2010	Feb 1, 2011	Diastolic Heart Failure
NCT00644332	Approved	Completed	Nov 1, 2007	Jan 1, 2011	Chronic Angina
NCT00091429	Phase 3	Completed	Aug 1, 2004	Feb 1, 2005	Angina

Competing Products

20 competing products in Hypertrophic Cardiomyopathy

See all competitors

Product	Company	Stage	Hype Score
Mavacamten	LianBio	Phase 1	19
Mavacamten + Placebo	LianBio	Phase 3	30
CT-G20 + Placebo	Celltrion	Phase 1	21
candesartan	AstraZeneca	Phase 2	31
LCZ696 + Placebo	Novartis	Phase 2	35
Eleclazine + Placebo	Gilead Sciences	Phase 2/3	30
PF-06473871 + PF-06473871	Pfizer	Phase 2	27
PF-06473871 + PF-06473871	Pfizer	Phase 2	35
EXC 001 + EXC 001 + EXC 001 + EXC 001	Pfizer	Phase 2	35
Mavacamten	Bristol Myers Squibb	Approved	50
Mavacamten + Placebo	Bristol Myers Squibb	Phase 3	44
Mavacamten	Bristol Myers Squibb	Pre-clinical	30
Mavacamten	Bristol Myers Squibb	Pre-clinical	33
Mavacamten	Bristol Myers Squibb	Approved	47
MYK-224	Bristol Myers Squibb	Phase 2	27
mavacamten	Bristol Myers Squibb	Phase 2/3	38
mavacamten	Bristol Myers Squibb	Phase 2	35
Mavacamten	Bristol Myers Squibb	Pre-clinical	33
Mavacamten	Bristol Myers Squibb	Pre-clinical	30
Mavacamten + Placebo	Bristol Myers Squibb	Phase 3	40